Therapeutic study of the nausea and vomiting caused by chemotherapy medications by olanzapine to triple antiemetic therapy in Iraqi cancer patients
DOI:
https://doi.org/10.32947/ajps.v23i2.1013Keywords:
chemotherapy induced nausea and vomiting (CINV), olanzapine, (MASCC) antiemetic tool.Abstract
Background:Chemotherapy-caused nausea and vomiting is a health problem in cancer patients. Olanzapine is used with serotonin receptor antagonists plus dexamethasone post Neurokinin 1 receptor antagonists as the antiemetic.
Objective: The study aimed to determine the efficacy of (5 and 10) mg of olanzapine with antiemetic drugs against chemotherapy-induced nausea and vomiting.
Methods: The study groups are Group S: received triple antiemetic therapy aprepitant at (1-3) day, dexamethasone at (1-4) day, and ondansetron only on the first day. Group O5: received olanzapine 5 mg with triple antiemetic therapy aprepitant (1-3) days, dexamethasone (1-4) day, ondansetron the first day, and olanzapine 5 mg (1-4) days. Group O10: received (olanzapine 10 mg with triple antiemetic therapy) aprepitant (1-3) days, dexamethasone (1-4) days, ondansetron day 1, and olanzapine 10 mg (1-4) days. The cancer was diagnosed by mamograph; the MAT score was used to control chemotherapy-caused nausea and vomiting.
Results: Higher acute and delayed nausea was observed in group S than in groups O5 and O10. Overall, nausea control was increased in group S than in groups O5 and O10. There was no significant difference between the different study groups.
Conclusion: Olanzapine 5 mg and 10 mg could treat nausea more than triple antiemetic in patients with nausea.
References
- Ibraheem S, Kadhim AA, Kadhim KA, Kadhim IA, Jabir M. Zinc Oxide Nanoparticles as Diagnostic Tool for Cancer Cells. International Journal of Biomaterials. 2022 Nov 2; 2022. DOI: https://doi.org/10.1155/2022/2807644
- Hameed GS, Sabar MH. Nano-carriers as a Selective Treatment for Cancer. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021;21 (1):55-66. DOI: https://doi.org/10.32947/ajps.v21i1.802
- Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Critical reviews in oncology/hematology. 2016; 99:13-36. DOI: https://doi.org/10.1016/j.critrevonc.2015.12.001
- Rashid AA, Mohammed Hussein RA, Hashim NW. Assessing the Quality of Life in Breast Cancer Women: A Cross Sectional Descriptive Study. Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2299-2307. doi: 10.31557 /APJCP.2022.23.7.2299. PMID: 35901335; PMCID: PMC9727348. DOI: https://doi.org/10.31557/APJCP.2022.23.7.2299
- Levy B. Supportive Care for Cancer Patients During and After Chemotherapy Treatment. Journal of Chinese Medicine. 2018(116).
- Cohen L, De Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings. Supportive care in cancer. 2007;15(5):497-503. DOI: https://doi.org/10.1007/s00520-006-0173-z
- Hayashi T, Shimokawa M, Matsuo K, Nishimura J, Iihara H, Nakano T, Egawa T. 5HT3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. Cancer Sci. 2021 Feb;112(2):744-750. doi: 10.1111/ cas.14757. Epub 2020 Dec 17. PMID: 33274555; PMCID: PMC7893986. Navari RM. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Management of Chemotherapy-Induced Nausea and Vomiting: Springer; 2016. p. 107-20. DOI: https://doi.org/10.1111/cas.14757
- Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, et al. efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological Cancer: KCOG-G1301 phase II trial. Supportive Care in Cancer. 2016;24(2):675-82. DOI: https://doi.org/10.1007/s00520-015-2829-z
- Nakagaki M, Barras M, Curley C, Butler JP, Kennedy GA. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer. 2017;25(2):607-13. DOI: https://doi.org/10.1007/s00520-016-3445-2
- Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage. 2007 Aug;34(2):148-59. doi: 10.1016/j. jpainsymman.2006.10.018. Epub 2007 May 23. PMID: 17509816. DOI: https://doi.org/10.1016/j.jpainsymman.2006.10.018
- Yoodee J, Permsuwan U, Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2017; 112:113-25. DOI: https://doi.org/10.1016/j.critrevonc.2017.02.017
- Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016;27: v119-v33. DOI: https://doi.org/10.1093/annonc/mdw270
- Guo X, Lin X. Observation on the curative effect of olanzapine combined with conventional antiemetic drugs on chemotherapy-associated vomiting. China Continuing Medical Education. 2018;10(22):124-6.
- He Y, Xi X, He F. The efficacy and safety of olanzapine in the treatment of highly and moderately emetogenic chemotherapy-induced nausea and vomiting. Med J West China. 2018;30(09):1315-8.
- Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International journal of clinical oncology. 2018;23(2):382-8. DOI: https://doi.org/10.1007/s10147-017-1200-4
- Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Supportive Care in Cancer. 2016;24(5):2381-92. DOI: https://doi.org/10.1007/s00520-016-3075-8
- Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2015;33 (29_suppl):176-176. DOI: https://doi.org/10.1200/jco.2015.33.29_suppl.176
- Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. The New England journal of medicine. 2016;375(2):134-42. DOI: https://doi.org/10.1056/NEJMoa1515725
- Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer. 2013;21(6):1655-63. DOI: https://doi.org/10.1007/s00520-012-1710-6
- Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Pain and Symptom Management. 2014;47(3):542-50. DOI: https://doi.org/10.1016/j.jpainsymman.2013.05.003
- Kadhim KA, Fadil SM. Effect the Pharmaceutical Care and Health Education on Knowledge and Disease Control for Type 2 Diabetes Mellitus Patients: A sample of Iraqi Patients. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2020 Jun 1;20(1):40-54. DOI: https://doi.org/10.32947/ajps.v20i1.684
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
